Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.56 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 7/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323766 | 0.83 | DPP7 (0.46) | DPP7DPP4MMP1MMP2MMP8 | |
| SCHEMBL5323770 | 0.83 | DPP7 (0.46) | DPP7DPP4MMP1MMP2MMP8 | |
| SCHEMBL16964809 | 0.82 | CYP3A4 (0.41) | DPP7MMP1MMP8ALDH1A1 | |
| SCHEMBL3056306 | 0.82 | CYP3A4 (0.41) | DPP7MMP1MMP8ALDH1A1 | |
| SCHEMBL8487636 | 0.79 | L3MBTL1 (0.42) | DPP7DPP4MMP1MMP2MMP8 | |
| SCHEMBL6820919 | 0.78 | DPP7 (0.59) | DPP7DPP4FAPDPP8DPP9 | |
| SCHEMBL1063045 | 0.78 | DPP7 (0.59) | DPP7DPP4FAPDPP8DPP9 | |
| SCHEMBL1063047 | 0.78 | DPP7 (0.59) | DPP7DPP4FAPDPP8DPP9 | |
| SCHEMBL8489074 | 0.78 | L3MBTL1 (0.44) | DPP7DPP4MMP1MMP2MMP8 | |
| SCHEMBL3066436 | 0.76 | DPP7 (0.60) | DPP7DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | US | disclosed |
| EP-1893194-A4 | ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1893194-A1 | ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060287381-A1 | Enhanced indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006127961-A1 | ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287381-A1 | Enhanced indolinone based protein kinase inhibitors | PHKG1, PHKG2, PRKCH | DPP7 2012/4885CPB2 2636/4885DPP4 2943/4885 |
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | PHKG1, PHKG2, PRKCH | DPP7 2387/4885CPB2 4001/4885DPP4 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.